linjc16/ctgov huggingface dataset:
Genetics of Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
Despite the developments in recent years, pulmonary arterial hypertension (PAH) is still a disease with high mortality and morbidity. Although studies on genetic background have increased, the pathogenesis of PAH remains complex and unresolved. The most comprehensive data are related to bone morphogenetic protein receptor type 2 (BMPR2), and in recent years, new responsible or candidate genes have been identified, especially by new generation DNA sequencing In this study, it was aimed to determine the genetic background of patients with PAH and to investigate the genetics of secondary PAH not only HPAH.

Detailed Description
-----------------
In our study, changes in BMPR2, SARS2, KRT8, KRT18, SMAD9, CAV1, KCKN3, CPS1, TBX4, ACVRL1, G6PC3, EIF2AK4 and ENG genes will be screened in patients with PAH. In addition to previously reported changes in the relevant genes, previously unreported changes that are likely to be significant according to insilico methods are presented. Patients' age, gender, mean follow-up time, underlying congenital heart anomalies, 6-minute walk test (6 MWT), proBNP, catheter measurement values (mPAB, m RAB, Rp/Rs, PVR), vasoreactivity test positivity, World health organization functional classification (WHO-FS), cardiac function measurements by echocardiography, treatments they received will be collected retrospectively.

Official Title
-----------------
Genetic Overview of Pulmonary Hypertension

Conditions
-----------------
Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mPAB ≥25 mmHg, pulmonary capillary wedge pressure (PCWP) ≤15 mmHg, PVR index (PVRI) ≥3 WU.m2 in right heart catheterization. Exclusion Criteria: Neonatal pulmonary hypertension

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetics of Pulmonary Hypertension | Determining the genetic background of patients with PAH and detecting genetic changes that may predispose to PAH in patients with secondary PAH other than HPAH. | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effects of mutations of Pulmonary Hypertension on disease | The effects of the detected mutations on the age of onset of the disease, the course of the disease and the response to treatment will be evaluated. | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genetics, pulmonary hypertension
Real Time Early Warning Model and Mobile Medical Assistant System for the Impact of Air Pollution on AECOPD Disease

Study Overview
=================
Brief Summary
-----------------
Objective to establish a real-time early warning model of acute exacerbation of chronic obstructive pulmonary disease (COPD) caused by air pollution, and develop the corresponding mobile medical assistant system. Through the cross fusion of existing information technology and medical research results, an auxiliary medical system is formed for information recording, tracking tools, early warning model and clinical diagnosis of patients with COPD.

Detailed Description
-----------------
Objective to establish a real-time early warning model of acute exacerbation of chronic obstructive pulmonary disease (COPD) caused by air pollution, and develop the corresponding mobile medical assistant system. Through the cross fusion of existing information technology and medical research results, an auxiliary medical system is formed for information recording, tracking tools, early warning model and clinical diagnosis of patients with COPD.

Official Title
-----------------
Real Time Early Warning Model and Mobile Medical Assistant System for the Impact of Air Pollution on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
COPD

Intervention / Treatment
-----------------
* Combination Product: Types and exposure of different air pollutants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged > 40 and < 80 years with post-bronchodilator FEV1/ forced vital capacity (FVC) < 0.7 and percentage predicted of FEV1>30%, who were no exacerbation of symptoms in the 6 weeks preceding the study, were included in the study. Exclusion Criteria: Patients who were diagnosed with other chronic respiratory diseases, including bronchial asthma, bronchiectasis and lung abscess. Patients with near-terminal illness, congestive heart failure (NYHA III-IV), or cannot record CAT score timely were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low air pollution<br> | Combination Product: Types and exposure of different air pollutants<br>* Types and exposure of different air pollutants in COPD patients' living and working environment<br>|
| High air pollution<br> | Combination Product: Types and exposure of different air pollutants<br>* Types and exposure of different air pollutants in COPD patients' living and working environment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of acute exacerbations | Frequency of acute exacerbations | 1 year incidence rate |
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)
* Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)
* Other: Timolol Vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 or older. Diagnosis of glaucoma or ocular hypertension. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Under 18. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Travoprost/Timolol<br> | Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)<br>* One drop in the study eye(s) once daily, 9 PM, for 6 weeks<br>* Other names: DuoTrav;Other: Timolol Vehicle<br>* One drop in the study eye(s) once daily for 6 weeks<br>|
| Active Comparator: Dorzolamide/Timolol<br> | Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)<br>* One drop in the study eye(s) twice daily for 6 weeks<br>* Other names: Cosopt;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Intra-Ocular Pressure (IOP) |  | 6 weeks |
Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

Study Overview
=================
Brief Summary
-----------------
This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.

Detailed Description
-----------------
Constraint-Induced Movement Therapy was developed to treat stroke hemiparesis. Due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from Constraint-Induced Movement Therapy.

Official Title
-----------------
Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Behavioral: Constraint-Induced Movement Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic upper extremity motor deficit due to multiple sclerosis Exclusion Criteria: Relapse within 3 months of planned enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Treatment with Constraint-Induced Movement Therapy | Behavioral: Constraint-Induced Movement Therapy<br>* Intensive practice with the hemiparetic arm for 30 contact hours<br>* Other names: CI Therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement on the Motor Activity Log |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement on the Wolf Motor Function Test |  | Pre to post-treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple sclerosis
The Effect of Washback on Reading Comprehension

Study Overview
=================
Brief Summary
-----------------
Testing and teaching are completely interrelated in education process; using various kinds of tests teachers are able to anticipate about the strong and weak points of learning in students, their progress and their accomplishment. The influence a test on teaching and learning is commonly referred to as washback. Testing washback is a twisted concept that becomes even more complex under a various interpretations of the washback phenomenon on teaching and learning. This study aimed to describe washback behaviors of students, in the low stakes testing in an ESP environment in two-fold. First, the study investigated the effects of different formative tests on Iranian medical students' English reading comprehension achievement. Secondly, the study explores the effects of washback on the students' attitudes toward English reading comprehension. The pre- and post-tests and one questionnaire were used to collect the data from Iranian medical students. Data were analyzed by paired t-test, t-test, and Mann-Whitney U test.

Conditions
-----------------
Reading Comprehension

Intervention / Treatment
-----------------
* Other: washback
* Other: routin intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: nursing students study at mums Exclusion Criteria: other disciplines study at other universities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: washback<br>students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test | Other: washback<br>* students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test<br>|
| Other: control<br>students only received two tests, Michigan test of English language proficiency as pre-test and post-test. | Other: routin intervention<br>* students only received two tests, Michigan test of English language proficiency as pre-test and post-test.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improving reading comprehension | improving reading comprehension scored by Michigan Test of English Proficiency | up to one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
washback, reading comprehension
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.

Detailed Description
-----------------
Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.

Official Title
-----------------
Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Conditions
-----------------
Candidiasis, Oral, HIV Infections

Intervention / Treatment
-----------------
* Drug: Posaconazole
* Drug: Fluconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria You may be eligible for this study if you: Are at least 18 years old. Are HIV-positive. Have thrush (oropharyngeal candidiasis). Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms). Are able to take study medication and return for clinic visits during the study. Are expected to live for at least 2 months. Exclusion Criteria You will not be eligible for this study if you: Have received protease inhibitors for the first time within 30 days prior to study entry. Have received certain medications. Have certain other types of fungal infections. Have certain types of cancer. Have received SCH 56592 within 3 months prior to study entry. Are pregnant or breast-feeding. Cannot take medications by mouth. Are allergic to azole drugs. Have certain medical conditions. Have been in this study before.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Posaconazole|nan|
|Drug: Fluconazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS-Related Opportunistic Infections, Fluconazole, Administration, Oral, Antifungal Agents, Candidiasis, Oral, Pharyngeal Diseases, posaconazole
1-Year Follow up to the 1473-IMIQ Study

Study Overview
=================
Brief Summary
-----------------
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.

Official Title
-----------------
A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study

Conditions
-----------------
Keratosis

Intervention / Treatment
-----------------
* Drug: Imiquimod 5% cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions Exclusion Criteria: Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Imiquimod 5% cream|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AK, Imiquimod 5% cream, 3M Pharmaceuticals, Aldara, Actinic Keratosis
Malnutrition is Not a Risk Factor for Free Flap Failure in the Oral Cavity

Study Overview
=================
Brief Summary
-----------------
Free flap reconstruction consists in replacing tissular defect from one body part by another tissu harvested in a distant site. Microsurgery has to be performed to restore vascularization. Free flaps are now the gold standard in complex reconstruction. While reliable with a success rate superior to 95 %, a failure takes a heavy burden on the patient. Many risk factors have been highlitghted in free flap failure for head and neck microvascular reconstruction. Among them, malnutrition is still debated. This is a retrospective cohort study comparing complications occurrence between two groups. One group with normal nutritionnal status, the other with malnutrition. Between january 2008 and january 2018, 70 patients who underwent oral cavity reconstruction using free flap were included. This is the first study known to date which uses clinical and biological variables to determine the nutritionnal status. Malnutrition is not associated with a higher risk for free flap failure in the oral cavity.

Official Title
-----------------
Malnutrition is Not a Risk Factor for Free Flap Failure in the Oral Cavity

Conditions
-----------------
Free Flap Reconstruction

Intervention / Treatment
-----------------
* Procedure: Free flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: every consenting patients undergoing free flap reconstruction of the oral cavity Exclusion Criteria: unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| None-malnutrition<br>normal nutritionnal status | Procedure: Free flap<br>* Free flap reconstruction of the oral cavity<br>|
| Malnutrition<br>weight loss was superior to 5% in the past month; a weight loss was superior to 10% in the past 6 months; a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to > 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to <35g/L (if age superior to 70 years old). | Procedure: Free flap<br>* Free flap reconstruction of the oral cavity<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major complication occurency | in the first-month post-operative period, complications leading to flap loss | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minor complication occurency | in the first-month post-operative period, complications NOT leading to flap loss | 1 month |
SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Study Overview
=================
Brief Summary
-----------------
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib

Official Title
-----------------
Effect of SBRT Combined With Osimertinib Compared With Osimertinib Alone for Stage IV Non-small Cell Lung Cancer

Conditions
-----------------
Stage IV Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Radiation: SBRT+Osimertinib
* Drug: Osimertinib 80 MG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have biopsy proven metastatic NSCLC (Stage IV). Patients receiving first-line Osimertinib for EGFR mutant-positive for 3 months and achieved stable disease or partial response. Age 18 to 75 years old. Patients must have measurable disease at baseline. The amount of metastatic focus <5. ECOG score 0-2 7 Adequate normal organ and marrow function for TKI treatment and radiotherapy. 8. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R) 9. Patients must provide written informed consent to participate in the study. Exclusion Criteria: Patients who previously received radiotherapy to the primary site. Patient can't tolerate radiotherapy or targeted therapy; Pregnant or nursing women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: SBRT plus Osimertinib versus Osimertinib
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Osimertinib plus SBRT<br>SBRT with photon and dose is 40Gy/5F after three months after Osimertinib treatment | Radiation: SBRT+Osimertinib<br>* Received SBRT after three months of Osimertinib treatment<br>|
| Active Comparator: Osimertinib<br>Osimertinib 80mg, po, Qd | Drug: Osimertinib 80 MG<br>* Osimertinib 80mg, po, Qd<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | the time from the beginning of Osimertinib treatment to disease progression or death | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | the time from the beginning of Osimertinib treatment to death | 3 years |